Publication:
Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe

dc.contributor.authorDonna S.H. Linen_US
dc.contributor.authorTzung Dau Wangen_US
dc.contributor.authorPeera Buranakitjaroenen_US
dc.contributor.authorChen Huan Chenen_US
dc.contributor.authorHao Min Chengen_US
dc.contributor.authorYook Chin Chiaen_US
dc.contributor.authorApichard Sukonthasarnen_US
dc.contributor.authorJam Chin Tayen_US
dc.contributor.authorBoon Wee Teoen_US
dc.contributor.authorYuda Turanaen_US
dc.contributor.authorJi Guang Wangen_US
dc.contributor.authorKazuomi Karioen_US
dc.contributor.otherSiriraj Hospitalen_US
dc.contributor.otherSunway Universityen_US
dc.contributor.otherJichi Medical Universityen_US
dc.contributor.otherShanghai Jiao Tong University School of Medicineen_US
dc.contributor.otherNational Taiwan University Hospitalen_US
dc.contributor.otherNational Yang-Ming University Taiwanen_US
dc.contributor.otherUniversitas Katolik Indonesia Atma Jayaen_US
dc.contributor.otherDepartment of Medicineen_US
dc.contributor.otherUniversiti Malayaen_US
dc.contributor.otherVeterans General Hospital-Taipeien_US
dc.contributor.otherTan Tock Seng Hospitalen_US
dc.contributor.otherChiang Mai Universityen_US
dc.date.accessioned2022-08-04T11:00:08Z
dc.date.available2022-08-04T11:00:08Z
dc.date.issued2021-03-01en_US
dc.description.abstractHypertension is a worldwide epidemic that continues to grow, with a subset of patients responding poorly to current treatment available. This is especially relevant in Asia, which constitutes 61% of the global population. Hypertension in Asia is a unique entity that is often salt-sensitive, nocturnal, and systolic predominant. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor that was first used in heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, a metallopeptidase that degrades natriuretic peptides (NPs). NPs exert sympatholytic, diuretic, natriuretic, vasodilatory, and insulin-sensitizing effects mostly via cyclic guanosine monophosphate (cGMP)-mediated pathways. As an antihypertensive agent, sacubitril/valsartan has outperformed angiotensin II receptor type 1 blockers (ARBs), with additional reductions of office systolic blood pressures ranging between 5 and 7 mmHg, in multiple studies in Asia and around the globe. The drug was well tolerated even in the elderly or those with chronic kidney disease. Its mechanisms of actions are particularly attractive for treatment of hypertension in Asia. Sacubitril/valsartan offers a novel, dual class, single-molecule property that may be considered as first-line antihypertensive therapy. Further investigations are needed to validate its safety for long-term use and to explore other potentials such as in the management of insulin resistance and obesity, which often coexist with hypertension in Asia.en_US
dc.identifier.citationJournal of Clinical Hypertension. Vol.23, No.3 (2021), 556-567en_US
dc.identifier.doi10.1111/jch.14120en_US
dc.identifier.issn17517176en_US
dc.identifier.issn15246175en_US
dc.identifier.other2-s2.0-85097424703en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/78423
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097424703&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleAngiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globeen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85097424703&origin=inwarden_US

Files

Collections